Group items tagged

Japanese drugmaker Eisai said on Tuesday (January 10) it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease. Nearly all previous experimental drugs using the same approach have failed. The company's application to the European Medicines Agency is based on results from a late-stage study in which the drug was shown to slow down the rate of cognitive decline in patients with early Alzheimer's by 27 per cent, compared with a placebo. Eisai also reiterated its plans to apply for marketing authorization of the drug in Japan by the end of its business year on March 31.

Pharmanovia, a global pharmaceutical company has announced increased targets to divert 40 per cent of its air shipments to sea in 2023, and 75 per cent by the end of 2028. It has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report. Its industry-leading air-to-sea pilot scheme, which focused on its Spain-to-Australia freight route, cut an estimated 470,000kg in potential CO2 emissions in 2022 - reducing Scope 3 upstream transport emissions by 18 per cent. This initiative demonstrates Pharmanovia's role as an industry leader on carbon reduction and follows a recent report which stated just 16 of 500 pharmaceutical companies measured their entire Scope 3 emissions. The new Sustainability Report reveals that the Scope 2 emissions decreasing by 13 per cent in 2022, due to lower direct electricity demand within the office space. The company's packaging audit seeing a 52 per cent increase in the percentage of products packed with at least one fully recyclable component, up from 12% in 2021 to 64 per cent in 2022 Strong progress in an initiative which saw Pharmanovia set ESG goals all employees across its global offices as part of annual performance awards. Employees achieved a 98 per cent completion rate of the compliance training, including ESG modules

Governments should invest in vaccines for all strains of influenza virus that exist in the animal kingdom as an insurance policy in case of an outbreak in humans, the incoming chief scientist at the World Health Organization said on Monday (Feb. 20). Countries ranging from the United States and Britain to France and Japan have suffered record losses of poultry in outbreaks of avian flu in the past year. The recent spread to mammals of H5N1 - commonly known as bird flu - needed to be monitored, but the risk to humans remained low, the WHO said earlier this month. Incoming WHO chief scientist Jeremy Farrar said he would like to see the pharmaceutical industry at least conduct some clinical trials for all influenza strains such that the world would not have to start from scratch to initiate global manufacturing should the need arise. "My concern that we're in slow motion watching something which may never happen," he added in a media briefing. "But if it were to happen, would we look back on what we're doing at the moment and say, why didn't we do more?"

Adults who are overweight or obese and have type 2 diabetes or prediabetes are at a higher risk of developing severe health issues, according to authors of a recent study. Experts. however, disagree on the best dietary regimens and supportive measures to suggest. The latest study was published in the journal 'The Annals of Family Medicine'. In the findings, researchers used a 2×2 diet-by-support factorial design to randomise 94 adults with the aforementioned conditions, contrasting a very low-carbohydrate (VLC) or ketogenic diet with a Dietary Approaches to Stop Hypertension (DASH) diet. They also determined the outcomes of interventions that included and excluded additional support practices like mindful eating, effective emotion regulation, social support, and cooking instruction. Using intent-to-treat analyses, the VLC diet led to greater improvement in estimated mean systolic blood pressure (SBP; -9.8 mmHg vs. -5.2 mmHg, P =.046), greater improvement in glycosylated haemoglobin (HbA1c; -.4 per cent vs. -.1 per cent, P = 0.034), and greater improvement in weight (-19.14 lbs vs. -10.33 lbs, P = 0.0003), compared to the DASH diet. The addition of extra support did not have a statistically significant effect on outcomes.

A change in medication can benefit patients on blood pressure-lowering therapies significantly more than increasing the dose of their current medication. A recent study from Uppsala University that was published in the Journal of the American Medical Association (JAMA) demonstrates this. In this study, four different blood pressure-lowering medications were tested out on 280 individuals over the course of a year. "The effect of a change of medication can be twice as great as the effect of doubling the dose of the patient's current medication. It was clear in our study that certain patients achieved lower blood pressure from one drug than from another. This effect is large enough to be clinically relevant," said Johan Sundstrom, cardiologist and Professor of Epidemiology at Uppsala University, who is the first author of the study. Most Swedes develop high blood pressure sooner or later; more than two million Swedes have high blood pressure at the present time. Only a fifth of them have managed to bring their blood pressure under control through drug therapy, and some studies suggest that only half of them take their blood pressure medication as intended. Could this be because the efficacy and side-effects of the drugs differ from individual to individual?

Technological innovation has touched our lives in immeasurable ways, from city infrastructure to personal entertainment and beyond. Even our health and conditions have been improved by the right tech innovations; contact lenses were one such innovation, having been safely pioneered as recently as the 19th century. But there are more recent developments which could change the lives of contact lens users forever; what are they? Smart Touch Contact Lenses While Smart Touch lenses are a relatively simple innovation, it is often the simple innovations that have the most fundamental impact on contact lens users. Smart Touch lenses are a new type of contact lens produced with a breathable material to promote eye health throughout the day. The key innovation lies in the packaging; Smart Touch contact lenses are provided in a bespoke blister packaging solution that delivers the lenses face-up. This ensures that the user never needs to touch the inner surface of the lens, keeping it hygienic and allowing for quick, unobtrusive application. These contact lenses provide innovative solutions for lens-wearers, and represent the power of slight technological improvements to existing products.

Diabetes drugs that also promote weight loss such as Novo Nordisk's Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimer's disease. Diabetes regimens, from Ozempic to old mainstays like insulin and metformin, appear to address several different aspects of the metabolic system implicated in Alzheimer's disease, including a protein called amyloid and inflammation, researchers say. The hope is that improving glucose utilisation and tamping down inflammation in the entire body - including the brain - could slow progression of debilitating diseases like Alzheimer's and Parkinson's. Several scientists interviewed by Reuters news agency pointed to mounting research supporting testing diabetes drugs against neurodegenerative diseases. Results are years away and success uncertain. But interest has been buoyed by recent positive data on Alzheimer's drugs developed by Eisai with partner Biogen and by Eli Lilly demonstrating that removing sticky amyloid plaques accumulated in the brain can slow cognition decline caused by the fatal mind-wasting disease. Those successes followed decades of futility that had left many questioning the validity of the amyloid theory behind most experimental Alzheimer's drugs.

In a recent announcement, Mundipharma, a leading global pharmaceutical company, has announced its acquisition of all assets and rights related to rezafungin from Cidara Therapeutics. This solidified Mundipharma's dedication to managing infectious diseases and specialty care therapeutic areas, especially invasisve candidiasis which over the 15 years has seen no new therapeutic developments underscoring for alternative options. The FDA and MHRA approved rezafungin is a groundbreaking once-weekly echinocandin antifungal drug specifically designed for the treatment of invasive candidiasis in adults. While Mundipharma will oversee global commercialization efforts, Melinta Therapeutics will retain commercialization rights for rezafungin in the United States. Moreover, the acquisition empowers the pharmaceutical company with global ownership of rezafungin, encompassing its ongoing development and distribution.

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects are extensive and significant. Countless individuals in these communities do not have sufficient access to dental care, confronting a harsh reality where a minor toothache can develop into a severe problem. This situation impacts more than just oral health; it also affects general well-being, job prospects, and even self-confidence. Recent studies reveal a startling picture of dental health disparities in these areas. Studies show that individuals residing in rural areas face a higher risk of tooth loss due to untreated decay and gum disease when compared to those living in urban areas with better access to dental care. Children miss school and adults miss work due to preventable dental problems. These statistics paint a bleak portrait of a healthcare gap that demands our immediate attention. Good dental health is not a luxury; it's a fundamental component of a healthy life. It contributes to our overall well-being, playing a role in preventing chronic diseases like diabetes and heart disease. The consequences of neglecting oral health can be devastating, leading to pain, infection, and even systemic health issues.

NHS England has launched a cloud-based platform that links recently-retired consultants, who still hold a licence to practice, with secondary care providers who need additional help with their waiting lists. It has been developed to make it easier and more flexible for retired doctors to return to the health service as part of the Long Term Workforce Plan. NHS chief executive Amanda Pritchard in June 2023 announced the NHS Emeritus pilot scheme, which is expected to help reduce long waits for elective care. Initially, the scheme will run for a year across England, and if successful, it may be expanded to cover other work areas. Health Minister Andrew Stephenson commented: "Returning consultants will bring invaluable experience and knowledge, and the new digital platform will match highly-skilled consultants with the NHS trusts that require their expertise, providing high quality care and alleviating pressures on high demand areas.

The UK Department of Health and Social Care (DHSC) has signed a new US$10 million (7.8 million pounds) grant agreement with global non-profit organisation, FIND. This extends the UK government's support to FIND through the Global AMR Innovation Fund (GAMRIF) for another four years. FIND recently announced the GAMRIF funding, which will be used to support its three-pronged strategy to prevent AMR emergence and halt its development. Dr Cassandra Kelly-Cirino, Vice President, Health Programmes at FIND, said: "Lack of essential diagnostics that can be accessed by people when and where they are needed is jeopardizing global efforts to combat AMR everywhere. We are grateful to GAMRIF for the continued support as we work in partnership on this multi-faceted strategy to save lives."